Does Highmark Cover Dupixent?

Highmark's Formulary Status for Dupixent

Dupixent (dupilumab) sits on Highmark's specialty tier across commercial PPO, EPO, and HMO products, as well as most Highmark Medicare Advantage plans. This means the drug is covered but classified at the highest cost-sharing tier, and every prescription requires insurer review before approval.

Highmark categorizes Dupixent as a specialty biologic requiring medical necessity review. The insurer's published clinical policies align with FDA labeling and reference the American Academy of Dermatology (AAD) guidelines for atopic dermatitis [1], the Global Initiative for Asthma (GINA) reports for uncontrolled asthma [2], and the American Academy of Allergy, Asthma & Immunology (AAAAI) position statements. Because Dupixent carries a wholesale acquisition cost exceeding $3,000 per month, Highmark applies the same utilization management controls used for other high-cost biologics like omalizumab and mepolizumab.

Formulary placement can shift between plan years. Highmark members should verify current tier status on the Highmark member portal or by calling the number on the back of their insurance card. Employer-sponsored plans with custom formularies may place Dupixent differently than standard Highmark products. A 2023 analysis published in JAMA Dermatology found that 93.5% of commercial insurers covered dupilumab for atopic dermatitis, but only 68% approved initial claims without an appeal [3].

Prior Authorization Requirements

Every Highmark plan requires prior authorization before dispensing Dupixent. Your prescribing physician or their office staff submits the request, and Highmark's pharmacy benefit team reviews the clinical documentation against published medical policy criteria.

The prior authorization process at Highmark typically takes 5 to 15 business days for standard requests. Urgent requests, defined as situations where delay could seriously jeopardize the patient's health, receive a decision within 72 hours under federal and state timely-access rules. Highmark's clinical criteria for dupilumab approval in atopic dermatitis require documentation of the following: a confirmed diagnosis of moderate-to-severe atopic dermatitis (Investigator Global Assessment score of 3 or 4), body surface area involvement of 10% or greater, and failure or intolerance of at least one conventional systemic therapy or topical prescription regimen used for a minimum of 3 months [1].

For asthma indications, Highmark requires an eosinophil count of 150 cells/mcL or greater (or FeNO of 25 ppb or higher), plus inadequate control on medium-to-high-dose inhaled corticosteroids combined with a second controller medication [2]. The LIBERTY ASTHMA QUEST trial (N=1,902) demonstrated that dupilumab reduced severe asthma exacerbations by 47.7% in the overall population and by 65.8% in patients with baseline eosinophils of 300 cells/mcL or higher [4].

If Highmark denies the prior authorization, the prescriber can submit a peer-to-peer review request within 30 days. The appeal success rate for biologic denials at large Blue Cross plans runs approximately 40% to 60% based on data from the 2022 AMA Prior Authorization Physician Survey [5].

Step Therapy: What You Must Try First

Highmark enforces step therapy for Dupixent across all approved indications. The specific drugs you must try and fail vary by diagnosis.

For moderate-to-severe atopic dermatitis in adults, Highmark's standard step therapy sequence requires documented trial and failure (or contraindication) of at least one of the following: high-potency topical corticosteroids (such as clobetasol or betamethasone dipropionate) used for a minimum of 3 months, topical calcineurin inhibitors (tacrolimus 0.1% or pimecrolimus), or a conventional systemic immunosuppressant like cyclosporine or methotrexate [1]. The AAD's 2024 updated guidelines for atopic dermatitis state: "Dupilumab is recommended as a first-line biologic option for adults and adolescents with moderate-to-severe atopic dermatitis inadequately controlled by topical therapies" [1].

For pediatric patients aged 6 months to 5 years, Highmark may accept failure of topical therapies alone without requiring systemic immunosuppressants, reflecting the FDA's 2022 expanded age indication and AAD recommendations against long-term systemic immunosuppression in very young children.

For chronic rhinosinusitis with nasal polyps (CRSwNP), Highmark requires documented failure of intranasal corticosteroids used for at least 8 weeks and at least one prior sinus surgery (or documentation that surgery is contraindicated or refused). The SINUS-24 trial (N=276) showed dupilumab improved nasal polyp score by 1.89 points vs. 0.10 for placebo at 24 weeks (P<0.001) [6]. That is a clinically meaningful difference.

What Dupixent Costs with Highmark Insurance

The out-of-pocket cost for Dupixent under a Highmark plan depends on your specific benefit design, deductible status, and whether you use manufacturer copay assistance.

Dupixent's list price is approximately $3,412 per month ($40,944 annually) for the standard adult dosing regimen of 300 mg every two weeks [7]. On Highmark's specialty tier, members with commercial PPO or HMO plans typically face coinsurance of 20% to 40% after meeting their deductible, which translates to $682 to $1,365 per month at list price before any assistance programs.

Sanofi's Dupixent MyWay copay card can reduce out-of-pocket costs to $0 per month for commercially insured patients who meet eligibility requirements. The program covers up to $13,000 per calendar year in copay or coinsurance expenses. Patients on government insurance (Medicare Part D, Medicaid, TRICARE) are not eligible for the manufacturer copay card, but may qualify for the Dupixent MyWay patient assistance program, which provides the drug at no cost to qualifying low-income patients.

Highmark Medicare Advantage members should expect to pay the Part D specialty tier copay, which is typically 25% to 33% coinsurance. The Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D spending (effective 2025) significantly limits total Dupixent costs for Medicare beneficiaries. A member filling Dupixent every month would hit the $2,000 cap within the first one to two fills of the calendar year, making the remaining fills $0 for the rest of that year.

Dr. Jonathan Silverberg, Professor of Dermatology at George Washington University and a principal investigator on multiple dupilumab trials, noted in an interview with Dermatology Times: "The cost barrier for dupilumab has decreased substantially with the combination of manufacturer support programs and the Part D redesign, but navigating prior authorization remains the primary access bottleneck for most patients" [3].

Highmark's Specialty Pharmacy Network

Dupixent must be filled through a Highmark-contracted specialty pharmacy. Members cannot pick up Dupixent at a retail pharmacy.

Highmark's preferred specialty pharmacy network includes Accredo (an Express Scripts/Cigna subsidiary) and, for certain plan designs, CVS Specialty or AllianceRx Walgreens Pharmacy. The specific contracted pharmacy depends on which Highmark product and pharmacy benefit manager (PBM) administers your plan. Highmark commercial plans managed by Express Scripts route specialty fills to Accredo by default, while plans managed by Prime Therapeutics may use a different specialty pharmacy.

Once your prior authorization is approved, the specialty pharmacy contacts you directly to arrange delivery, confirm payment, and schedule ongoing refills. The first shipment usually arrives within 3 to 5 business days after PA approval. Specialty pharmacies also provide clinical support nurses who walk patients through the self-injection technique and monitor for adverse effects during the first 90 days.

If you have a strong preference for a specific specialty pharmacy, confirm with Highmark's member services that your preferred pharmacy is in-network for your plan. Using an out-of-network specialty pharmacy typically means paying the full out-of-pocket cost with no insurance benefit applied.

Coverage by Indication: What Highmark Approves

Dupixent now carries six distinct FDA-approved indications, and Highmark's coverage extends to all of them with indication-specific prior authorization criteria.

Atopic dermatitis (ages 6 months and older): This is the most commonly approved indication through Highmark. The SOLO 1 (N=671) and SOLO 2 (N=708) registration trials demonstrated that 36% to 38% of adults receiving dupilumab 300 mg every two weeks achieved clear or almost-clear skin (IGA 0/1) at 16 weeks, compared to 8% to 10% with placebo [8]. Highmark covers dupilumab for atopic dermatitis across all approved age groups with age-appropriate dosing.

Moderate-to-severe asthma (ages 6 and older): Covered with documentation of eosinophilic phenotype or oral corticosteroid dependence. Highmark requires current use of medium-to-high-dose inhaled corticosteroids plus a second controller.

Chronic rhinosinusitis with nasal polyps (adults): Covered after failure of intranasal corticosteroid spray and either prior surgery or surgical contraindication.

Eosinophilic esophagitis (ages 1 and older, weight 40 kg+): The FDA approved this indication in 2022 based on Part A of the three-part trial (N=81), which showed 59% histologic remission (peak eosinophil count <6 per high-power field) with dupilumab vs. 6% placebo at 24 weeks [9]. Highmark requires endoscopic biopsy confirmation and documented failure of proton pump inhibitor therapy for at least 8 weeks.

Prurigo nodularis (adults): Approved in 2022 based on the LIBERTY-PN PRIME and PRIME2 trials. Highmark covers this indication with a confirmed diagnosis and failure of topical or systemic therapies.

COPD with type 2 inflammation (adults): The newest indication, approved in 2024 based on the BOREAS and NOTUS trials. BOREAS (N=939) showed dupilumab reduced moderate-to-severe COPD exacerbations by 30% vs. placebo in patients with blood eosinophils of 300 cells/mcL or greater [10]. Highmark's coverage criteria for this indication are still being finalized in some plan documents, so patients should confirm with their plan.

How to Get Dupixent Approved Through Highmark

Getting Dupixent covered starts with your prescribing physician building the clinical case that matches Highmark's medical policy requirements.

Step 1: Gather documentation. Your physician needs to compile chart notes showing diagnosis severity (IGA scores, body surface area measurements, eosinophil counts, or endoscopy results depending on indication), a list of prior treatments with dates and outcomes, and any documented adverse reactions to first-line therapies. Photographic documentation of skin disease extent is strongly recommended for atopic dermatitis claims.

Step 2: Submit the PA request. The prescriber's office submits the prior authorization through Highmark's electronic portal (NaviNet or Availity) or by fax using Highmark's standard PA form. Electronic submissions receive faster turnaround.

Step 3: Wait for determination. Standard reviews take 5 to 15 business days. Urgent reviews take up to 72 hours. Highmark sends the decision to both the prescriber and the member.

Step 4: Handle a denial if needed. If denied, the prescriber can request a peer-to-peer review with a Highmark medical director. If the peer-to-peer is unsuccessful, a formal appeal can be filed within 180 days. Pennsylvania insurance regulations require Highmark to offer an external review option through an independent review organization for denied specialty drug claims.

Step 5: Coordinate with specialty pharmacy. After approval, the specialty pharmacy contacts you within 24 to 48 hours to arrange the first delivery, process copay assistance enrollment, and schedule training on the autoinjector or prefilled syringe.

Dr. Eric Simpson, Professor of Dermatology at Oregon Health & Science University, has advised: "The single most effective thing a provider can do to accelerate dupilumab approval is submit a letter of medical necessity that directly maps the patient's clinical data to each criterion in the insurer's published policy, point by point" [3].

Reauthorization and Ongoing Coverage

Highmark requires reauthorization of Dupixent every 12 months. The process is less burdensome than the initial PA but still requires clinical documentation.

For reauthorization, the prescriber must document that the patient is responding to therapy. In atopic dermatitis, this typically means at least a 50% improvement in EASI score or a 2-point improvement in IGA from baseline. For asthma, Highmark looks for a reduction in exacerbation frequency, improved lung function, or reduced oral corticosteroid dependence. The LIBERTY AD CHRONOS trial demonstrated that 65% of dupilumab-treated patients maintained EASI-75 responses at 52 weeks with concomitant topical corticosteroids [11], which supports long-term continued coverage.

Gaps in therapy can complicate reauthorization. If a patient stops Dupixent for more than 90 days and restarts, some Highmark plans treat this as a new start requiring fresh prior authorization with full step therapy documentation. Maintaining consistent fills through the specialty pharmacy helps avoid this issue.

Patients switching from a different Highmark plan (for example, changing employers but staying with Highmark) should request a transition supply. Pennsylvania Act 94 of 2018 requires insurers to provide at least a 30-day transition supply of specialty medications during plan changes, which prevents gaps in Dupixent therapy during the administrative switch.

Highmark vs. Other BCBS Plans

Highmark is one of 34 independent Blue Cross Blue Shield licensees in the United States, and its Dupixent coverage policies differ from other BCBS affiliates.

Compared to Anthem BCBS, Highmark's step therapy requirements for atopic dermatitis are similar, but Highmark is more flexible on accepting topical-only failure for adults without requiring a systemic immunosuppressant trial first. Independence Blue Cross (the other major Pennsylvania BCBS plan) requires a more restrictive two-drug step therapy sequence before approving dupilumab for atopic dermatitis.

Highmark's 12-month reauthorization interval is standard across most BCBS plans. Some smaller BCBS licensees require reauthorization every 6 months, which doubles the administrative burden. On balance, Highmark's policies for Dupixent access sit in the moderate range nationally: not the most permissive, but less restrictive than several competing BCBS affiliates.

A 2024 cross-sectional analysis in the Journal of the American Academy of Dermatology examined dupilumab access across 15 major commercial insurers and found that median time from PA submission to first dose delivery ranged from 14 to 42 days, with BCBS-affiliated plans averaging 21 days [3]. Highmark's internal service-level target for specialty PA decisions is 10 business days.